Recent Episodes
Watch recent episodes on
PTV News Review
Scroll Left
Scroll Right
Nektar Therapeutics: Inhaling Success: An Interview with John Patton, CSO and Co-founder




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Nektar Therapeutics: Inhaling Success: An Interview with John Patton, CSO and Co-founder
Released on: February 01, 2007. © PharmaVentures Ltd
Visitors: You are watching a 5 minute preview.
Get more information and subscribe now
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Fintan Walton talks to John Patton, CSO and Co-founder of Nektar Therapeutics about the challenges he faced in setting up the firm and the company’s success to date.
  • Summary
  • Transcript
  • Participants
  • Company
Fintan Walton talks to John Patton, CSO and Co-founder of Nektar Therapeutics about the challenges he faced in setting up the firm and the company’s success to date. John describes how his research at Genentech on inhaled proteins prompted him to set up Nektar (then Inhale Therapeutic Systems), and discusses the resistance he faced from traditional players in the diabetes market when seeking partners.

Since its deals with GlaxoSmithKline and Pfizer in 2004 - both for Nektar’s PEGylation technology - and its subsequent acquisition of Aerogen, the 1.3billion-dollar company has gone from strength to strength. John outlines the business strategy for Nektar going forward and also discusses the company’s product pipeline.
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
John S. Patton is a world-renowned expert in the delivery of peptides and proteins. Before co-founding Inhale Therapeutic Systems, he led the drug delivery group at Genentech, where he demonstrated the feasibility of systemic delivery of large molecules through the lungs.

Prior to joining Genentech, Dr Patton was a tenured professor at the University of Georgia. He has published a wide range of scientific articles and has presented his work in national and international arenas. Dr Patton received his PhD in biology from the University of California, San Diego, and held post-doctoral positions in biomedicine at Harvard Medical School and the University of Lund in Sweden.
Nektar Therapeutics